Paysign loads donors' fees onto prepaid cards for plasma collectors. For drug makers it checks copay claims, pays the patient's share and bills the maker back.
The company · 2 · What exactly does it sell?
Drug makers now edge out plasma
Each $1 of sales, second quarter of 2026
52%46%2%
Copay help for drug makersPlasma donor cardsOther
The copay side more than doubled; the plasma side is losing centres.
The company · 3 · How does it make money?
Fees per card and per claim
$110Msales in the past year
21%operating profit per $1
113plasma centres leaving by year-end
Overhead grows far slower than sales, so each new dollar adds profit.
Is it a good business? · 4 · What gives it an edge?
Switching is a nuisance, not a wall
47.7%
of US plasma centres use it
$325M
client savings it claims, unverified
When collectors sell centres, the new owner can move them to another provider, though every donor then needs a new card.
Is it a good business? · 5 · What is the catch?
A far larger rival runs the same service
McKessonsaves patients about $10B a year
Onbeprivate, sells the same donor cards
Haemoneticsplasma software linked to its machines
Listed rivals: MCK · HAE
Paysign saves patients about $1B a year against McKesson's $10B.
Is it a good business? · 6 · What does its record show?
Sales more than tripled, profit widened
Sales, $M
29.5
38.0
47.3
58.4
82.0
109.8
Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025last 12 mo
Sales$29.5M → $110Msales, 2021 to the past year
Profit−9.3% → 21%operating profit per $1
Kept50% → 63%kept per $1 after serving it
The shift to drug makers lifted what it keeps per dollar.
Is it a good business? · 7 · How much room is there to grow?
Copay is the bigger pool
$23Bdrug makers spent on copay aid in 2023
About $115.2Ma year if every US plasma centre paid its rate
Nearly $1Bof copay aid Paysign handled in 2025
Nobody publishes what administrators earn on the copay pool, so its size in fees is unknown.
Is it a good business? · 8 · Who is in charge?
The co-founder runs it with a big stake
2006Mark Newcomer began running it
16.3%of the company he owns
24.5%owned by officers and directors
Insiders own a lot, though they have been selling.
The story right now · 9 · Why do drug makers pay copays?
Drug makers pay patients' share to keep them
$23Bcopay aid in 2023
85%growth in Paysign's drug-maker sales, first half
Expensive drugs often leave patients a large share to pay. Drug makers cover it and pay firms like Paysign to run it; a federal rule against plans that drain that aid could remove its main appeal.
The story right now · 10 · Why is plasma shrinking?
A big customer is moving 113 centres
Collectors sell centresNew owners choose.
113 centres move awayBy year-end.
About $11.3M a yearOf revenue leaving.
Copay must make it upGrowing fast.
Paysign expects 445 to 450 centres at year-end, down from 562.
The story right now · 11 · What changed lately?
Sales up 43% as plasma centres leave
$30.8Mrevenue in the third quarter
23.8%operating profit per $1, from 7.3%
About $11.3Ma year of revenue leaving
29.3%share jump after second-quarter results
Solid quarter
The shares doubled, mostly as buyers paid more per dollar of sales.
The story right now · 12 · What is everyone arguing about?
A fast grower, or bad news in the notes?
Many investors think
A fast-growing healthcare payments company
We think
Real copay growth, already in the price
The centre losses and a failed software purchase sit in the notes. Against us: it keeps beating and raising forecasts.
The price and our view · 13 · What is a share worth?
The price sits above even our best case
$6.62what we think a share is worth · the last close is of that
$6.62our value
Attractive below $5.30
Neutral
Unattractive above $7.94
$3.32gloomy: growth halves, less kept per $1
$6.62our estimate: experts' path, then slowing
$9.07sunny: growth beats the forecast by a quarter
Value per share in three futures. None is a prediction of the share price.
We estimate what a share is worth from the cash the business should earn over many years. Our rule: buy only when the price is at least a fifth below our estimate, as a cushion for being wrong.
The price and our view · 14 · What if it all works?
As a bet on copay programmes, it is fragile
Priced for successthe kind of bet this is
0.8×if it works
44%kept if it fails
Multiples of the company's value when the bet was last struck, 1 Oct 2026.
The price already pays for copay success, and a little under half is left if the programmes stall.
The price and our view · 15 · How could we be wrong?
A rule could remove its appeal
A rule on copay aidBiggest
Its main pitch.
Plasma centres leavingShowing now
113 by year-end.
McKesson's sizeWatch
Ten times bigger.
Fees on copayUnknown
Not published.
Insiders are selling, and collectors can move centres when they sell them.
The price and our view · 16 · How will we know?
March brings the first 2027 forecast
Copay growth keeps paceGood sign
Plasma losses stop at 113Good sign
A copay rule is adoptedBad sign
MAR 202710
Fourth-quarter and full-year 2026 results, 10 March. Companies report every three months; each report is a test of the story.
Our view also changes on price alone: if the shares fall to within a fifth of our estimate, we move to Neutral.
The price and our view · 17 · So, what do we think?
Fast copay growth, a shrinking plasma business
$6.62our value
Attractive below $5.30
Neutral
Unattractive above $7.94
UnattractiveHigh conviction
Paysign's copay side more than doubled with real profit. But a rule could remove its main appeal, a plasma customer is moving 113 centres away, and the price sits above even our sunny future.
↑ ↓ to move · C for contents
What it does
More about the company
Who it is
Plasma collectors pay donors a fee after each visit. Paysign loads that fee onto a prepaid card, and CSL Plasma, one of the largest collectors, sends its donors to Paysign's app.
Drug makers help insured patients with the part of a drug's price their insurance leaves them to pay. Paysign runs those programs: it checks each claim at the pharmacy, pays the patient's share from the maker's fund and bills the maker back. The alternative is a rival administrator such as McKesson.
How it makes money
From plasma, it earns a fee each time a donor spends from the card: about $7,699 a month per center in Q2 2026. From drug makers, it earns set-up, monthly and per-claim fees, not a share of the money it pays out. More programs and more claims bring more fees. Nothing is paid on a percentage of the aid itself.
Growth and profit
What growth costs
Growth has made Paysign steadily more profitable. Office, sales and admin costs rise much more slowly than sales, so each new dollar of revenue keeps more profit. It reports no research spending; it builds its software and spreads that cost over later years instead.
Its record
The numbers
Is it growing?Fast
Sales grew 47% over the twelve months to Sep 2026, faster than the 40% in the year to Dec 2025.
Is it profitable?Strong
Operating margin is 21%, up from −0.4% in the year to Dec 2023.
Does growth pay off?Pays off
Running costs take 42¢ of each sales dollar, down from 59¢ in the year to Dec 2021.
Does it earn good returns?Strong
Each dollar put into the business earns 28% a year after tax, up from 2.1% in the year to Dec 2022.
Is it making cash?Strong
It turned 118% of sales into free cash, $130M over the last twelve months.
How steady is it?Uneven
Yearly sales growth has ranged from +22% to +40% over the last 5 years.
Are shares being diluted?Diluting
The share count rose 23% in 4.8 years, and pay in shares costs 4.8% of sales.
Why it wins
The evidence
Switching is a nuisance. A collector that leaves must give every donor a new card, and a drug maker that moves a program risks patients' claims failing at the counter. Paysign holds 47.7% of US plasma centers by an outside count.
Its pitch to drug makers is catching insurers' plans that drain copay funds; those plans took $2.7B in 2023. Paysign says its rules saved clients $325M in 2025, but only Paysign measured that. And when collectors sell centers, the cards leave with them.
Who could beat it
The rivals in full
McKesson runs the same copay service at a far larger scale, saving patients about $10B a year against Paysign's $1B. Onbe, a private company, sells the same donor cards. For plasma software, Haemonetics already sells a cleared system linked to its own collection machines; Paysign's has no clearance.
Each rival
McKesson Prescription Technology SolutionsMCK
The whole copay program: enrolment, the card, adjudication at the pharmacy and reporting to the drug maker.
Onbeprivate
The donor card and payout itself: a collector moves its centers' donor payments to Onbe's cards.
Haemonetics NexLynk DMSHAE
The donor management software a center runs, already FDA-cleared and wired to Haemonetics' own collection machine.
How big it could get
The market and who has signed
The market
If all 1,247 US plasma centers paid Paysign's current rate, plasma cards would bring in about $115.2M a year, against $45.62M in 2025. Paysign already has nearly half of them, so that business can grow mainly by taking more per center.
Drug makers spent $23B on copay aid in 2023; Paysign handled nearly $1B in 2025. Nobody publishes what administrators earn on that pool, so its size in fees is unknown.
Who runs it
Leaders, pay and the cash
Who runs it
Mark Newcomer co-founded the business and has run it since 2006; he owns about a sixth of the company, and officers and directors together about a quarter, so management gains or loses with shareholders. Pay is loosely tied to results: bonuses are set by the board at its discretion, and most share awards vest simply by staying, with some tied to profit targets the company does not publish.
The last report
The latest report
Paysign's sales rose 43%, profit guidance rose, and 113 plasma centers are leaving
What it did to the thesis Solid quarter
Every number the thesis asked for came in, so the copay business is growing fast with real profit. The 113 centers cost plasma revenue, and the call did not change that. The shares remain dear, so the view stays Unattractive.
The report
Q3 2026 revenue was $30.8M, up 42.6%. Copay programs more than doubled in sales, to $16.6M, and the operating margin rose to 23.8% from 7.3% with no one-off gain. The company raised its profit forecast and kept its sales forecast.
Against that, a plasma customer said 113 of its centers will move to another provider by year-end, about $11.3M a year of revenue. Paysign expects about 445 to 450 centers at year-end, down from 562.
On the call, management said the customer is leaving for its banking partner, not over service, and expects to win replacements. The 10-Q says the loss reaches into 2027.
What's happening now
The background
The shares more than doubled in a year, and most of the rise came from buyers paying more for each dollar of sales rather than from sales themselves. They jumped 29.3% the day after the Q2 2026 results.
The next test is the Q4 report, expected in March 2027, with Paysign's first guide for 2027 and its center count after 113 leave.
Where we disagree
Both sides in full
The market
Paysign is a fast-growing healthcare payments company, and the plasma worries and drug-policy fears are behind it.
We believe
The copay growth is real, but 113 plasma centers are leaving, the software purchase failed, and the price already pays for years of fast growth.
The argument
The market reads the headline figures. The center losses and the cancelled payment on the failed purchase sit in the notes and in the release's last paragraphs, not in its opening lines.
The case against us: the company keeps beating its own quarterly forecast and raising its profit forecast, and if copay programs keep compounding, today's price will look cheap.
What it's worth
How we value it
Valued on the analysts' revenue path for three years, each later year closing 30% of the gap to 4%, on official operating profit with stock pay a cost and tax paid in full; the thesis's own evidence is the check on that path.
What the price assumes
Sales growth in the first year, then slowing as ours does, at the same profit per sale.
The price assumed
50.6%
Our estimate
17%
Measured at the close of
9 Nov 2026
The three cases
Bear case$3.32
Growth runs at half the analysts' path, 9% and 10%, the margin settles a fifth lower at 12.7%, and new capital earns only the 8% rate: the downturn test.
Our value$6.62
Revenue grows 17% and 19% over the next two years, the analysts' path (C54) measured from the twelve months to September, then fades toward 4%, closing 30% of the gap each year; the margin moves to 15.8%, the analysts' year-three figure after stock pay.
Bull case$9.07
Growth runs a quarter above the analysts' path, 21% and 24%, the margin reaches 17.4%, and new capital earns 15%.
The bet
Seen as a bet
This bet is on one business only: the drug-copay programs, which grow far faster than the rest. Paying plasma donors, the older half, is counted separately at the price the market paid for the company when it was mostly plasma.
If copay programs keep being added at their recent pace for two more years, the stock is worth less than today, so this is an expensive bet. If the copay business stalls, the plasma half and the stalled copay business cover a little under half of today's price.
What could go wrong
Every risk
The risks
A rule against copay-draining plans
Paysign's selling point is blocking insurers' maximizer plans. A federal ban would shrink the problem it is paid to solve.
One drug maker looms large
A single client is 36% of the money Paysign is owed, up from 31% at the end of 2025.
Plasma centers walking away
A customer is moving 113 centers, about $11.3M of yearly sales, to another provider by year-end; 33 net centers went in the last year.
A far larger rival
McKesson's copay service saves patients about $10B a year to Paysign's $1B, and programs Paysign wins from others can be won back.
Insiders are selling
Twenty open-market sales and no purchases in a year; share count up 7.1%.
What we still do not know
How many copay programs Paysign loses to rivals. It reports only the net count.
What it charges per program and per claim, against McKesson and private rivals. Nobody publishes it.
Which collector sold centers to a rival card provider, and which provider won them.
When, if ever, the FDA clears its plasma software.
What changes our view
Every route to a new view
Every route to a new view
→ Neutral
The share price falls to about $7.94, back within 20% of what we think the business is worth.
→ Attractive
The share price falls to about $5.30, 80% of what we think the business is worth.
→ Attractive
Paysign guides 2027 revenue of $150M or more, about 30% growth. Its plasma center count is at or above 445 at the end of 2026, once 113 centers leave, with no further customer moving.
The next test
It supports the case if
2027 revenue guidance at or above $150M, programs at or above 190, centers at or above 445 with no further customer moving, operating margin at or above 21% with no one-off gain, or an open-market purchase by a senior officer.
It pressures the case if
2027 revenue guidance below $150M, or programs below 190, or centers below 445, or operating margin below 21% once one-offs are removed.
We would also be wrong if
A federal rule bars insurers' maximizer plans in employer health plans.
One drug maker's bills pass half of what Paysign is owed, or a top-ten maker leaves.
The verdict
Scores and how we weighed it
The scores
Growth
3 of 4
Business quality
3 of 4
Financial position
4 of 4
Execution record
3 of 4
Per share capture
3 of 4
Potential
2 of 4
Risk profile
3 of 4
Valuation
1 of 4
Evidence quality
3 of 4
How we weighed it
ValueNegative
The price sits above our value and above the bull case.
BusinessPositive
A solid business whose copay side more than doubled with real profit.
GrowthMixed
The price needs drug makers to keep adding programmes at a fast pace.
RisksNegative
A rule may remove its main appeal, one client is a large share and plasma centres are leaving.
RivalsMixed
No filed rival compares directly; against its own normal it is far dearer.
The groupMixed
Fintech names move together on credit and rate news.
Latest newsPositive
The last report delivered every number the thesis asked for.
In plain words
Our estimate of value
We forecast how much cash the business can earn over the next ten years and beyond, then ask what that stream is worth today to an investor who wants an 8% yearly return. We do it three times: a gloomy future, an expected one and a sunny one. We call a share Attractive only when its price is at least 20% below the expected estimate, and Unattractive when it is 20% above.